Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Charles J. Ryan, MD; and Neal D. Shore, MD, FACS; answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:
Presenters:
Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota
Neal D. Shore, MD, FACS
Director
Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
Podcast on ongoing and planned clinical trials using PARP inhibitors in combination with other therapies in patients with prostate cancer from Clinical Care Options (CCO)
In this slideset from Clinical Care Options (CCO), experts provide insights on clinical trials of PARP inhibitor combinations in prostate cancer
In this slideset from Clinical Care Options (CCO), experts present the rationale for PARP inhibitor combination therapies in prostate cancer
Podcast on the rationale for using PARP inhibitors in combination with other therapies in patients with prostate cancer from Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.